Avantium (AVTX) H2 2024 earnings summary

Executive summary

• Completed construction of the world's first commercial FDCA Flagship Plant, with start-up scheduled for H1 2025 and commercial PEF sales expected in H2 2025, enabling commercial-scale sales and licensing strategy advancement.

• Secured commitments and offtake agreements from leading global brands across packaging, textiles, and consumer goods, positioning for future revenue growth.

• Achieved FDA approval for PEF in US food contact applications and expanded regulatory clearances in China, Europe, and the US.

• Developed breakthrough technology for recycling polycotton textile waste into glucose and PET, supporting a feedstock-agnostic approach and aligning with new regulatory trends.

• Secured €116.2 million in new financing (equity and loans) to support higher-than-anticipated CAPEX and ongoing operations.

Financial highlights

• Revenue increased to €21.0 million in 2024 from €19.7 million in 2023, a 6.6–7% year-over-year growth.

• EBITDA loss widened to €-33.3 million in 2024 from €-27.5 million in 2023, reflecting higher operating expenses.

• Net loss narrowed to €32.6 million from €34.2 million in 2023.

• Cash position declined to €23.9 million at year-end 2024 from €35.2 million in 2023, mainly due to FDCA plant CAPEX.

• Final FDCA Flagship Plant CAPEX reached €189 million (excluding €31.7 million capitalized interest).

Outlook and guidance

• Priority for 2025 is safe and successful start-up of the FDCA Flagship Plant, with first FDCA production expected in coming months.

• Commercial PEF sales under offtake agreements to begin in H2 2025 after regulatory validation.

• Licensing strategy to expand post-2025, leveraging flagship plant validation and diversified feedstock technologies.

• Actively pursuing additional funding, cost management, and strategic alternatives for non-core businesses.